Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases
Journal of Medicinal Chemistry · 11.06.2026 · 69 (11) · 12830-12852
DOI: 10.1021/acs.jmedchem.5c03753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.05.2026. Verfasst von Jincong Zhuo und 29 weiteren Autor:innen. Beteiligte Einrichtung: Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, Delaware 19803, United States. Hauptthemen laut MEDLINE: Janus Kinase 1, Autoimmune Diseases, Inflammation, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Incyte.
Abstract (Originalsprache)
Aberrant JAK2 signaling is a key driver in cancers such as myeloproliferative neoplasms (MPNs), whereas JAK1 acts as a central mediator of autoimmune and inflammatory diseases. Since JAK2 supports blood cell production, its inhibition can lead to anemia and other cytopenias, making selective JAK1 inhibition a potentially safer therapeutic strategy opposed to dual JAK1/JAK2 inhibition. We initially identified novel scaffold 9, which selectively inhibited JAK1 over JAK2. Iterative breakthroughs led to the discovery of povorcitinib (INCB054707, 22), which showed improved pharmacokinetics due to intramolecular hydrogen bonding of the amide moiety and a reduced ring size in the hinge binding motif. Protein crystallography suggested that JAK1 selectivity was conferred by the amide’s alkyl group accessing a small lipophilic groove formed by the P-loop conformation of JAK1 that was distinct from JAK2. In murine arthritis models, povorcitinib demonstrated dose-dependent efficacy and reduced inflammatory signaling, supporting its therapeutic potential in immunological disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, Delaware 19803, United States.
ORCID-Profile: David M Burns, Krista Burke, Brian Metcalf
Förderung
- Incyte
Zitieren
APA
Zhuo, J., Li, Y. L., Qian, D. Q., Burns, D. M., Mei, S., Rafalski, M., Xu, M., Cao, G., Pan, Y., Jia, Z., Jalluri, R., Epling, L. B., Fenalti, G., Deller, M. C., Procak, J., Covington, M., He, X., Collins, R., Stubbs, M., …, & Yao, W. (2026). Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases. Journal of Medicinal Chemistry, 69(11), 12830-12852. https://doi.org/10.1021/acs.jmedchem.5c03753
Vancouver
Zhuo J, Li YL, Qian DQ, Burns DM, Mei S, Rafalski M, et al. Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases. Journal of Medicinal Chemistry. 2026;69(11):12830-12852. doi:10.1021/acs.jmedchem.5c03753
BibTeX
@article{Zhuo2026,
author = {Zhuo, Jincong and Li, Yun-Long and Qian, Ding-Quan and Burns, David M and Mei, Song and Rafalski, Maria and Xu, Meizhong and Cao, Ganfeng and Pan, Yongchun and Jia, Zhongjiang and Jalluri, Ravi and Epling, Leslie B and Fenalti, Gustavo and Deller, Marc C and Procak, Jessica and Covington, Maryanne and He, Xin and Collins, Robert and Stubbs, Matthew and Burke, Krista and Oliver, Julian and Margulis, Alex and Boer, Jason and Wynn, Richard and Scherle, Peggy and Diamond, Sharon and Newton, Robert and Zhang, Yan and Metcalf, Brian and Yao, Wenqing},
title = {Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {11},
pages = {12830--12852},
doi = {10.1021/acs.jmedchem.5c03753}
}
EUVIMED